Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

Journal of Clinical Oncology

Volumn 23, Issue 26, 2005, Pages 6364-6369

  Fernàndez, Veronica ^a   Hartmann, Elena ^a   Ott, German ^a   Campo, Elias ^a   Rosenwald, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; PROTEIN MDM2; PROTEIN P16INK4A; PROTEIN P53; CYCLIN DEPENDENT KINASE; ONCOPROTEIN;

ALLELE; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CHROMOSOME 14; CHROMOSOME TRANSLOCATION; DNA DAMAGE; EXON; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY; HUMAN; MANTLE CELL LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; UPREGULATION; CELL CYCLE; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RISK FACTOR;

CELL CYCLE; CYCLIN D1; CYCLIN-DEPENDENT KINASES; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; ONCOGENE PROTEINS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 27244434794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.019     Document Type: Review

References (55)

1. Jaffe ES, Harris NL, Stein H, et al (eds.): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
2. Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 36:115-127, 1999
3. Swerdlow SH, Williams ME: From centro-cytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
4. Lardelli P, Bookman MA, Sundeen J, et al: Lymphocytic lymphoma of intermediate differentiation: Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 14:752-763, 1990
5. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
6. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
7. Bernard M, Gressin R, Lefrere F, et al: Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype. Leukemia 15:1785-1791, 2001
8. Ott G, Kalla J, Ott MM, et al: Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89:1421-1429, 1997
9. Hunter T, Pines J: Cyclins and cancer: II. Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994
10. Williams ME, Swerdlow SH, Rosenberg CL, et al: Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 52:5541s-5544s, 1992
11. Tsujimoto Y, Jaffe E, Cossman J, et al: Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315:340-343, 1985
12. Tsujimoto Y, Yunis J, Onorato-Showe L, et al: Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 224:1403-1406, 1984
13. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bell-linked candidate oncogene, Nature 350:512-515, 1991
14. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, et al: Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 10:1833-1840, 1995
15. Bosch F, Jares P, Campo E, et al: PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma. Blood 84:2726-2732, 1994
16. Arnold A, Kim HG, Gaz RD, et al: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83:2034-2040, 1989
17. Rosenberg CL, Wong E, Petty EM, et al: PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638-9642, 1991
18. Rimokh R, Berger F, Bastard C, et al: Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 83:3689-3696, 1994
19. Lin S, Wang W, Wilson GM, et al: Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol 20:7903-7913, 2000
20. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al: A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 9:1925-1929, 1994
21. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
22. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
23. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2:103-112, 2002
24. Quintanilla-Martinez L, Davies-Hill T, Fend F, et al: Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): Implications for pathogenesis. Blood 101:3181-3187, 2003
25. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619-626, 2000
26. Gronbaek K, Nedergaard T, Andersen MK, et al: Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: A genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 12:1266-1271, 1998
27. Pinyol M, Hernandez L, Cazorla M, et al: Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272-280, 1997
28. Pinyol M, Cobo F, Bea S, et al: p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984, 1998
29. Dreyling MH, Bullinger L, Ott G, et al: Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57:4608-4614, 1997
30. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
31. Jacobs JJ, Kieboom K, Marino S, et al: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168, 1999
32. Bea S, Tort F, Pinyol M, et al: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412, 2001
33. Randle DH, Zindy F, Sherr CJ, et al: Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci U S A 98:9654-9659, 2001
34. Kamijo T, Weber JD, Zambetti G, et al: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95:8292-8297, 1998
35. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
36. Pinyol M, Hernandez L, Martinez A, et al: INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156:1987-1996, 2000
37. Hernandez L, Bea S, Pinyol M, et al: CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Research 65:2199-2206, 2005
38. Bentz M, Plesch A, Bullinger L, et al: t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27:285-294, 2000
39. Monni O, Oinonen R, Elonen E, et al: Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21:298-307, 1998
40. Stilgenbauer S, Winkler D, Ott G, et al: Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 94:3262-3264, 1999
41. Camacho E, Hernandez L, Hernandez S, et al: ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99:238-244, 2002
42. Schaffner C, Idler I, Stilgenbauer S, et al: Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 97:2773-2778, 2000
43. Fang NY, Greiner TC, Weisenburger DD, et al: Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci U S A 100:5372-5377, 2003
44. Zhou BB, Elledge SJ: The DNA damage response: Putting checkpoints in perspective. Nature 408:433-439, 2000
45. Kastan MB, Zhan Q, el-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992
46. Perkins EJ, Nair A, Cowley DO, et al: Sensing of intermediates in V(D)J recombination by ATM. Genes Dev 16:159-164, 2002
47. Kussie PH, Gorina S, Marechal V, et al: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953, 1996
48. Peng CY, Graves PR, Thoma RS, et al: Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501-1505, 1997
49. Tort F, Hernandez S, Bea S, et al: CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100:4602-4608, 2002
50. Hangaishi A, Ogawa S, Qiao Y, et al: Mutations of Chk2 in primary hematopoietic neoplasms. Blood 99:3075-3077, 2002
51. Tort F, Hernandez S, Bea S, et al: Check-point kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19:112-117, 2005
52. Prives C: Signaling to p53: Breaking the MDM2-p53 circuit. Cell 95:5-8, 1998
53. Greiner TC, Moynihan MJ, Chan WC, et al: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
54. Louie DC, Offit K, Jaslow R, et al: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86:2892-2899, 1995
55. Hernandez L, Fest T, Cazorla M, et al: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351-3359, 1996